Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > A question for all
View:
Post by BlueFranky on Feb 09, 2021 2:02pm

A question for all

To everyone concerned If someone close to you expressed an interest in reading the most compelling pieces of information, pointing toTLT ad a case of when, not if... which links would you provide? Thank you in advance
Comment by Johnandrose22 on Feb 09, 2021 2:21pm
May I suggest news releases: July 31 and September 30, 2019 indicating Phase I patients 5 and 6 being cancer free for 18 months after a single treatment.
Comment by Rumpl3StiltSkin on Feb 09, 2021 2:44pm
The best stuff lately is the speculative stuff, and most of that is locked in prior posts here on this Sh Bullboard: Will RP take up 1433 in their upcoming phase 1 for NSCLS, giving TLT a freebie Phase 1 and large animal interstitial models? Will U of M and Dr. Combs give us some great small animal data that will lead to a cheap effective Covid 19 treatment and vaccine? This time the Cad govt ...more  
Comment by TriumphSpitSix on Feb 09, 2021 2:47pm
1. NR re: Ph. 1b terminated early due to achieving primary and secondary endpoints. 2. FDA Fast Track NR (showing FDA recognizes the potential superiority of Theralase PDT over current standard of care) 3. Latest Quarterly Newsletter with an update on Ph2 results and the opening of the first 4 US study sites 4. Pre-clinical rat studies are fascinating as well... (100% kill rate across the board ...more  
Comment by Jaro1977 on Feb 09, 2021 3:11pm
BlueFranky https://theralase.com/anti-cancer-therapy/pipeline/ This page puts everything at the click of a button, all thats in the works and all the peer reviewed papers.  This drug, TLD-1433 and Rutherrin are the greatest discovery of my lifetime and will change the future.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250